Ravi Sarode
YOU?
Author Swipe
View article: Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial Open
Background: Transfusion has a persistent low risk of transfusion-transmitted infection and transfusion-associated graft- versus -host disease that may be addressed using pathogen reduction. The Red Cell Pathogen Inactivation (ReCePI) trial…
View article: Pathogen‐reduced cryoprecipitate: Early experiences and inventory management
Pathogen‐reduced cryoprecipitate: Early experiences and inventory management Open
Background Room temperature storage of cryoprecipitated antihemophilic factor (CryoAHF) is limited to 6 h. Consequently, this product is stored frozen until requested, necessitating thawing and delaying fibrinogen supplementation. The FDA …
View article: Deep Learning-Based Approach for Disease Stage Classification of Sunflower Leaf
Deep Learning-Based Approach for Disease Stage Classification of Sunflower Leaf Open
Accurate disease severity evaluation is crucial for managing the disease and yield loss. The classification of disease stages is essential for the estimation of disease severity. It takes extensive time for cultivators and botanical resear…
View article: Efficacy of a Standardized Regimen of Therapeutic Plasma Exchange and <scp>IVIG</scp> for Treatment of Antibody‐Mediated Rejection in Lung Transplant Recipients
Efficacy of a Standardized Regimen of Therapeutic Plasma Exchange and <span>IVIG</span> for Treatment of Antibody‐Mediated Rejection in Lung Transplant Recipients Open
Antibody‐mediated rejection (AMR) in lung transplantation has been associated with poor long‐term clinical course and is a risk factor for chronic lung allograft dysfunction and graft loss. Appropriate management of AMR is necessary to imp…
View article: Physician perspectives about the diagnosis and management of acute chest syndrome
Physician perspectives about the diagnosis and management of acute chest syndrome Open
Background Acute chest syndrome (ACS) is the leading cause of mortality, accounting for 25% of all deaths among individuals with sickle cell disease (SCD). There is a lack of evidence‐based laboratory and clinical risk stratification guide…
View article: How do we manage hyperhemolysis syndrome
How do we manage hyperhemolysis syndrome Open
Background Hyperhemolysis syndrome (HHS) is a catastrophic anemia characterized by destruction of both donor and patient red blood cells (RBC). HHS occurs after transfusion and can cause significant morbidity and mortality. Given the diffi…
View article: Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score Analysis
Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score Analysis Open
Background Early in the COVID-19 pandemic, patients with severe disease admitted to the intensive care unit (ICU) had a high incidence of mortality. We aimed to investigate whether plasma adsorption with the MTx.100 Column could improve su…
View article: Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates
Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates Open
Importance Millions of people take vitamin K antagonists (VKAs). Some people who need urgent surgical procedures require rapid VKA reversal to prevent excessive intraoperative bleeding. Objective To evaluate the hemostatic noninferiority o…
View article: Tailoring caplacizumab administration using ADAMTS13 activity for immune-mediated thrombotic thrombocytopenic purpura
Tailoring caplacizumab administration using ADAMTS13 activity for immune-mediated thrombotic thrombocytopenic purpura Open
Caplacizumab, a nanobody targeting the A1 domain of von Willebrand factor (VWF), rapidly inhibits VWF interaction with platelets. This inhibition effectively prevents microthrombus formation and has led to its increasing use as a frontline…
View article: A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis
A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis Open
Background Plasma exchange (PLEX) therapy is indicated for several disorders. The 5% albumin is often used as a sole replacement fluid during most PLEX. However, each 1.0 plasma volume exchange depletes coagulation factors by ~65%. Althoug…
View article: Evaluation of an automated von Willebrand factor glycoprotein IbM activity assay compared with 3 alternative von Willebrand factor activity assays
Evaluation of an automated von Willebrand factor glycoprotein IbM activity assay compared with 3 alternative von Willebrand factor activity assays Open
The characteristics of the INNOVANCE VWF Ac assay regarding comparability with other VWF activity assays, reference ranges, and precision support the use of this assay for evaluation of patients with concern for von Willebrand disease.
View article: High annualized bleeding rates in pediatric patients with inherited platelet function disorders
High annualized bleeding rates in pediatric patients with inherited platelet function disorders Open
Not available.
View article: Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study—protocol for a phase 3, randomized, controlled trial
Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study—protocol for a phase 3, randomized, controlled trial Open
Background Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from bacteria, eme…
View article: Evaluation of the Efficacy &amp; Safety of Amustaline/Glutathione Pathogen Reduced RBCs in Complex Cardiac Surgery: the Red Cell Pathogen Inactivation (ReCePI) Study - Protocol for a Phase 3, Randomized, Controlled Trial
Evaluation of the Efficacy & Safety of Amustaline/Glutathione Pathogen Reduced RBCs in Complex Cardiac Surgery: the Red Cell Pathogen Inactivation (ReCePI) Study - Protocol for a Phase 3, Randomized, Controlled Trial Open
Background Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from bacteria, eme…
View article: Provider Perspectives on Diagnosis and Management of Acute Chest Syndrome
Provider Perspectives on Diagnosis and Management of Acute Chest Syndrome Open
Introduction: Acute chest syndrome (ACS) is the leading cause of mortality, accounting for 25% of all deaths among individuals with sickle cell disease (SCD). The etiologies and clinical manifestations of ACS are variable, with a lack of c…
View article: PB1032 Four-Factor Prothrombin Complex Concentrates for Vitamin K Antagonist Reversal before Urgent Surgery: Dosing and Hemostatic Efficacy in a Double-Blind Randomized Study
PB1032 Four-Factor Prothrombin Complex Concentrates for Vitamin K Antagonist Reversal before Urgent Surgery: Dosing and Hemostatic Efficacy in a Double-Blind Randomized Study Open
limited bleeding, and no thrombotic events.
View article: PB1360 High Annualized Bleeding Rates in Pediatric Patients with Mild Inherited Platelet Function Defects (IPFD)
PB1360 High Annualized Bleeding Rates in Pediatric Patients with Mild Inherited Platelet Function Defects (IPFD) Open
Conclusion(s): DGKKO is protective against both the thrombocytopenic and thrombotic effects of HIT IgGs in a small number of tested patients, being the first agent to prevent thrombocytopenia and reduce thrombus size post-HIT antibody expo…
View article: Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review
Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review Open
Summary Immune thrombotic thrombocytopenic purpura (iTTP) is a rare and life‐threatening haematological condition. Initial treatment involves plasma exchange (PLEX), corticosteroids, caplacizumab and rituximab. In relapsed and refractory c…
View article: Hemoglobin S target of <50% as compared to 30% in chronic red cell exchange for secondary stroke prevention in sickle cell disease
Hemoglobin S target of <50% as compared to 30% in chronic red cell exchange for secondary stroke prevention in sickle cell disease Open
Background Sickle cell disease (SCD) patients with a history of stroke are encouraged to receive chronic red blood cell exchange (RBCx) for stroke prevention. The American Society of Hematology guideline published in 2020 recommends an HbS…
View article: Acute Chest Syndrome in Sickle Cell Disease
Acute Chest Syndrome in Sickle Cell Disease Open
Acute chest syndrome (ACS) is the leading cause of mortality among individuals with sickle cell disease (SCD) accounting for 25% of all deaths. The etiologies and clinical manifestations of ACS are variable among children and adults, with …